FTSV News and Press, Forty Seven Inc.

Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadth of haematologic cancers as CD47 targeting drugs. Shares have rallied over...

Jounce Therapeutics ( JNCE ) is a small biotechnology company focused on the rapidly expanding industry of immuno-oncology. Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a penchant for striking lucrative deals with big pharma, the future...

Lately, interest for Gilead ( GILD ) stock has risen dramatically as a consequence of a potential launch of its COVID-19 drug named Remdesivir. I have been a long-term believer in this company. My investment thesis, also discussed in my December article , is based on three factors: its new ma...

The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...

For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...

Shares of Forty Seven   (NASDAQ: FTSV) climbed 64.5% in March, according to data from  S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences&#...

Merger activity increased last week with one new deal announced and seven deals closing. At a time when more than 10 deals trade with spreads of over 30% and 23 trade with spreads of over 10%, it is encouraging to see so many deals close including the acquisition of Sprint by T-Mobile (TMUS). ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

If you threw a dart at a dartboard covered with every stock ticker on the market, the odds are overwhelmingly in favor of you hitting a stock that's down so far in 2020. Only a few have managed to rise in the midst of the massive meltdown caused by the novel coronavirus pandemic. Even fewer have...

Gilead Sciences (NASDAQ: GILD) created the antiviral drug Remdesivir as a possible treatment for Ebola and the Marburg virus, and it's since been found to be potentially effective in treating COVID-19, the disease caused by the novel coronavirus. Some investors think this could mean signific...